<DOC>
	<DOCNO>NCT01657253</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ophthalmic solution PRO-148 ocular surface patient mild moderate dry eye compare ophthalmic solution Systane®</brief_summary>
	<brief_title>Efficacy Safety PRO-148 Versus Systane® , Patients With Mild Moderate Dry Eye</brief_title>
	<detailed_description>Dry eye multifactorial disease tear ocular surface result symptoms discomfort , visual disturbance , tear film instability potential damage ocular surface . Current treatment heavily weight toward supplementation , stimulation , preservation aqueous tear . Artificial tear one primary treatment dry eye ; mainly palliative focus reduce symptom discomfort improve quality life patient . A phase III randomize double-blind clinical trial conduct evaluate efficacy safety ophthalmic solution PRO-148 ocular surface patient mild moderate dry eye compare ophthalmic solution Systane® . Patients randomize receive one treatments 60 day . Efficacy safety measure perform baseline 60 day treatment</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Mild moderate dry eye patient base Report International Dry Eye Workshop ( DEWS ) OSDI score 12 45 Provided informed consent Patients one blind eye Visual acuity 20/100 bad eye Patients active ocular disease would interfere study interpretation Patients treatment medication could interfere study , contraindication medication use protocol Patients history hypersensitivity contraindication drug use study Contact lens user Pregnant patient , risk pregnancy breastfeed Patients without birth control treatment Patients participate clinical trial last 90 day Legal mentally disable patient could give informed consent Patients provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>